Neuroleptic malignant syndrome is characterized by altered mental status, muscle rigidity, hyperthermia, and autonomic hyperactivity that occur when certain neuroleptic drugs are used. Clinically, neuroleptic malignant syndrome resembles malignant hyperthermia. Diagnosis is clinical. Treatment is aggressive supportive care.

Among patients taking neuroleptic drugs, about 0.02 to 3% develop neuroleptic malignant syndrome. Patients of all ages can be affected.

Etiology

Many antipsychotics and antiemetics can be causative (see Table 3: Heat Illness: Drugs That Can Cause Neuroleptic Malignant Syndrome). The factor common to all drug causes is a decrease in dopaminergic transmission; however, the reaction is not allergic but rather idiosyncratic. Etiology and mechanism are unknown. Risk factors appear to include high drug doses, rapid dose increases, parenteral administration, and switching from one potentially causative drug to another.

Neuroleptic malignant syndrome can also occur in patients withdrawing from levodopa or dopamineSome Trade Names
INTROPIN
Click for Drug Monograph
agonists.

Table 3
PrintOpen table
Drugs That Can Cause Neuroleptic Malignant Syndrome Class Drugs Antipsychotics, traditional ChlorpromazineSome Trade Names THORAZINE Click for Drug Monograph FluphenazineSome Trade Names PROLIXIN DECANOATE PROLIXIN Click for Drug Monograph HaloperidolSome Trade Names HALDOL Click for Drug Monograph LoxapineSome Trade Names LOXITANE Click for Drug Monograph MesoridazineSome Trade Names SERENTIL MolindoneSome Trade Names MOBAN PerphenazineSome Trade Names TRILAFON Click for Drug Monograph PimozideSome Trade Names ORAP Click for Drug Monograph ThioridazineSome Trade Names MELLARIL Click for Drug Monograph ThiothixeneSome Trade Names NAVANE Click for Drug Monograph TrifluoperazineSome Trade Names STELAZINE Click for Drug Monograph Antipsychotics, newer AripiprazoleSome Trade Names ABILIFY Click for Drug Monograph ClozapineSome Trade Names CLOZARIL Click for Drug Monograph OlanzapineSome Trade Names ZYPREXA Click for Drug Monograph Paliperidone QuetiapineSome Trade Names SEROQUEL Click for Drug Monograph RisperidoneSome Trade Names RISPERDAL Click for Drug Monograph ZiprasidoneSome Trade Names GEODON Click for Drug Monograph Antiemetics Domperidone DroperidolSome Trade Names INAPSINE Click for Drug Monograph MetoclopramideSome Trade Names REGLAN Click for Drug Monograph ProchlorperazineSome Trade Names COMPAZINE Click for Drug Monograph PromethazineSome Trade Names PHENERGAN Click for Drug Monograph

Symptoms and Signs

Symptoms begin most often during the first 2 wk of treatment but may occur earlier or after many years.

The 4 characteristic symptoms usually develop over a few days and often in the following order:

• Altered mental status: Usually the earliest manifestation is a change in mental status, often an agitated delirium, and may progress to lethargy or unresponsiveness (reflecting encephalopathy).
• Motor abnormalities: Patients may have generalized, severe muscle rigidity (sometimes with simultaneous tremor, leading to cogwheel rigidity), or, less often, dystonias, chorea, or other abnormalities. Reflex responses tend to be decreased.
• Hyperthermia: Temperature is usually > 38° C and often > 40° C.
• Autonomic hyperactivity: Autonomic activity is increased, tending to cause tachycardia, arrhythmias, tachypnea, and labile hypertension.

Diagnosis

• Clinical evaluation
• Exclusion of other disorders and complications

The diagnosis should be suspected based on clinical findings. Early manifestations can be missed because mental status changes may be overlooked or dismissed in patients with psychosis.

Other disorders can cause similar findings. For example:

• Serotonin syndrome (see Heat Illness: Serotonin Syndrome) tends to cause rigidity, hyperthermia, and autonomic hyperactivity, but it is usually caused by SSRIs, and patients typically have hyperreflexia. Also, temperature elevations and muscle rigidity are usually less severe than in neuroleptic malignant syndrome, and nausea and diarrhea may precede serotonin syndrome.
• Malignant hyperthermia (see Heat Illness: Malignant Hyperthermia) and withdrawal of intrathecal baclofenSome Trade Names
  LIORESAL
  Click for Drug Monograph
  can cause findings similar to those of neuroleptic malignant syndrome, but they are usually easily differentiated by history.
• Systemic infections, including sepsis (see Sepsis and Septic Shock), pneumonia, and CNS infection, can cause altered mental status, hyperthermia, and tachypnea and tachycardia, but generalized motor abnormalities are not expected. Also, in neuroleptic malignant syndrome, unlike most infections, altered mental status and motor abnormalities tend to precede hyperthermia.

There are no confirmatory tests, but patients should have testing for complications, including serum electrolytes, BUN, creatinine, glucose, Ca, Mg, and CK, urine myoglobin, and usually neuroimaging and CSF analysis. EEG may be done to exclude nonconvulsive status epilepticus.

Treatment

• Rapid cooling, control of agitation, and other aggressive supportive measures

The causative drug is stopped and complications are treated supportively, usually in an ICU. Severe hyperthermia is treated very aggressively, mainly with physical cooling (see Heat Illness: Treatment). Some patients may require tracheal intubation and induced coma. Benzodiazepines, given IV in high doses, can be used to control agitation. Adjunctive drug therapy can be used, although efficacy has not been shown in clinical trials. DantroleneSome Trade Names
DANTRIUM
Click for Drug Monograph
(0.25 to 2 mg/kg IV q 6 to 12 h; maximum of 10 mg/kg/24 h) can be given for hyperthermia. BromocriptineSome Trade Names
PARLODEL
Click for Drug Monograph
(2.5 mg q 6 to 8 h) or, alternatively, amantadineSome Trade Names
SYMMETREL
Click for Drug Monograph
(100 to 200 mg q 12 h) can be given po or via NGT to help restore some dopaminergic activity. This condition may not respond to even rapid and aggressive therapy, and mortality in treated cases is about 10 to 20%.

Last full review/revision February 2010 by James P. Knochel, MD

Content last modified February 2012